Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGU

Multi-cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study

Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd Krause, Michael Lassmann, Walter Jentzen, Daniela Chicco, Patrick Klein, Lars Blumenstein, Jean-Rene Basque and Jens Kurth
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 2626;
Ken Herrmann
1Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kambiz Rahbar
2Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Eiber
3Technical University Munich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Sparks
4CDE Dosimetry Services, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Baca
5CDE Dosimetry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Krause
6Rostock University Medical Center, Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Lassmann
7Julius-Maximilians-Universität Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Jentzen
1Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Chicco
8Advanced Accelerator Applications, a Novartis Company, Turin, Piedmont, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Klein
9Novartis Institutes for BioMedical Research, East Hanover, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Blumenstein
10Novartis Institutes for BioMedical Research, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Rene Basque
11Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Kurth
6Rostock University Medical Center, Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Figures & Data

Figures

  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Multi-cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Multi-cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd Krause, Michael Lassmann, Walter Jentzen, Daniela Chicco, Patrick Klein, Lars Blumenstein, Jean-Rene Basque, Jens Kurth
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2626;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Multi-cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd Krause, Michael Lassmann, Walter Jentzen, Daniela Chicco, Patrick Klein, Lars Blumenstein, Jean-Rene Basque, Jens Kurth
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2626;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Initial Experience with F18-DCFPyL PET/CT for Metastatic or Biochemically Recurrent Prostate Cancer: A Single Institution Review
  • Imaging Prognosis of a Negative 68Ga-PSMA-1 PET Scan on Followup Studies
  • Comparison of Diagnostic Sensitivity Between [18F]Florastamin and [18F]FDG PET/CT in the Patients with Prostate Cancer
Show more GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire